Healthcare · Profile from Healthcare Research Companion
Lyra Health, Inc.
The Burlingame, California employer mental-health benefit founded by former Facebook and Genentech CFO David Ebersman. It replaced the traditional employee assistance program (EAP) for large companies with fast access to a vetted network of therapists, coaches and psychiatric prescribers plus its own employed clinicians. It became one of the most valuable private digital health companies (~$5.6bn in January 2022), bought the global EAP provider ICAS to go international, and by 2025–26 was pushing into pediatric care, high-acuity "centers of excellence" and what it calls clinical-grade AI, while still selling mostly to the employer benefits budget.
At a glance
- Founded
- June 2015, Burlingame, California (product launched to first employers in early 2016)
- Founders
- David Ebersman (CEO; CFO of Genentech, then Facebook 2009–2014) and Dena Bravata (co-founder and first chief medical officer; left in 2016, reported)
- Headquarters
- Burlingame, California
- Ownership / structure
- Private, venture-backed; investors include Greylock, Venrock, Casdin, IVP, Meritech, Addition, Dragoneer, Coatue, Salesforce Ventures, Fidelity, Baillie Gifford, Durable Capital and others (reported)
- Leadership (2026)
- David Ebersman, co-founder and CEO; Sandra Beaver, CFO (from June 2025); clinical leadership through Lyra Clinical Associates (verify current titles)
- Segment and buyer
- Behavioral health benefits (digital health / provider): buyer is the large employer (self-insured benefits budget), increasingly also health plans and benefits platforms; users are employees and dependants, including children
- Scale
- >2m covered members (2020); ~10m after the ICAS deal (January 2022); >17m people (late 2024, company; not re-confirmed), nearly 20m (March 2025) and >20m (from August 2025) through direct employer contracts, plus >100m reachable through health-plan and partner relationships (company figures); revenue not disclosed
- Capital raised / valuation
- >$900m raised (reported totals ~$890m–$915m); last priced round $235m led by Dragoneer at ~$5.58bn (January 2022, often rounded to ~$5.6bn); no later priced round confirmed
- Signature moves (incl. failures)
- Founding with $35m Series A (2015); employer EAP replacement with a curated network and blended care (2016); Starbucks benefit and unicorn round (2020); three mega-rounds in just under 12 months (January 2021–January 2022); ICAS acquisition (2022); therapist-incentive and data-use criticism (2022); ~2% non-clinical layoffs (2024); Centers of Excellence and Bend Health acquisition (2025); clinical-grade AI guide (2025–26)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2015
Founding and Series A
Founding / funding round
2016
Employer EAP Replacement Model
Launch / business model
2020
Starbucks Benefit and Unicorn Round
Partnership (major employer contract) / funding round
2021
Mega Rounds Addition and Coatue
Funding round (two rounds in six months)
2022
ICAS Acquisition and Series F
Acquisition / funding round
2022
Therapist Incentive and Data Criticism
Controversy / governance (public scrutiny of operating model)
2025
Centers of Excellence and Bend Health
Launch / acquisition
2025
Clinical Grade AI Guide
AI launch